A recent study reveals that people who stop using popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle plans.
Findings released in a leading medical journal shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users buying these treatments should be informed of the potential of fast weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original weight in about 18 months.
Comparing Treatments
The research, which reviewed dozens of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Researchers point out that people who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Experts propose the mode of action of the drugs accounts for the amplified rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines advise the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, considering the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is echoed by drug manufacturers, who say that the results "emphasize the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
Individuals who have come off the medication describe a intense resurgence of cravings.
"I experienced a switch that goes on and you become ravenous," described one woman.
This challenge is compounded if users have not developed lasting lifestyle or habit changes during therapy.
Growing Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone fix and long-term success likely depends on combined behavioural changes.
